ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient For 170,000 Doses Of ANKTIVA
Portfolio Pulse from Benzinga Newsdesk
ImmunityBio, Inc. (IBRX) has completed the drug substance for ANKTIVA, sufficient for 170,000 doses, and announced its GMP fill-finish facility in New York is on track for completion in 12-18 months. This progress, along with a partnership with the Serum Institute of India for BCG availability, positions ImmunityBio for the commercial launch and clinical trials of ANKTIVA. Significant investments have been made in facilities for global capacity, with a California manufacturing plant also nearing completion to support large-scale production.
May 07, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ImmunityBio has completed the drug substance for ANKTIVA, sufficient for 170,000 doses, and is advancing with its GMP fill-finish facility in New York, alongside a partnership with the Serum Institute of India for BCG availability.
The completion of the drug substance for ANKTIVA and the progress on the GMP fill-finish facility, coupled with the partnership for BCG availability, are significant milestones for ImmunityBio. These developments are likely to positively impact investor sentiment and the stock price in the short term, as they demonstrate progress towards commercialization and clinical trials of ANKTIVA. The company's strategic investments in manufacturing capacity and partnerships are critical for its long-term vision and future growth, making this news highly relevant and important for investors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100